Immunoconjugates against solid tumors: Mind the gap

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 4, 2011, Pages 513-523

  Ricart, A D ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CETUXIMAB; DOCETAXEL; DOXORUBICIN; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMGN 242; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOTOXIN; INTERFERON; INTERLEUKIN 2; LABETUZUMAB; LORVOTUZUMAB MERTANSINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BR 96; NEURADIAB; OFATUMUMAB; PANITUMUMAB; PEMTUMOMAB; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TAXANE DERIVATIVE; TOSITUMOMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER RESEARCH; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG SPECIFICITY; DRUG TARGETING; EDEMA; FATIGUE; GLIOBLASTOMA; HEMATEMESIS; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOALBUMINEMIA; IMMUNE RESPONSE; INTERSTITIAL FLUID; LYMPHOMA; METASTASIS; MICROMETASTASIS; MULTICENTER STUDY (TOPIC); NAUSEA; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG COSTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; IMMUNOCONJUGATES; NEOPLASMS; QUALITY OF LIFE;

EID: 79952992903     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.8     Document Type: Article

References (50)

1. Köhler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495-497 (1975).
2. Blattman, J.N. & Greenberg, P.D. Cancer immunotherapy: a treatment for the masses. Science 305, 200-205 (2004). (Pubitemid 38886725)
3. Lin, M.Z., Teitell, M.A. & Schiller, G.J. The evolution of antibodies into versatile tumor-targeting agents. Clin. Cancer Res. 11, 129-138 (2005). (Pubitemid 40075787)
4. Breedveld, F.C. Therapeutic monoclonal antibodies. Lancet 355, 735-740 (2000). (Pubitemid 30107636)
5. Brekke, O.H. & Sandlie, I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2, 52-62 (2003). (Pubitemid 37361624)
6. Goodman, G.E., Beaumier, P., Hellström, I., Fernyhough, B. & Hellström, K.E. Pilot trial of murine monoclonal antibodies in patients with advanced melanoma. J. Clin. Oncol. 3, 340-352 (1985). (Pubitemid 15132002)
7. Better, M., Chang, C.P., Robinson, R.R. & Horwitz, A.H. Escherichia coli secretion of an active chimeric antibody fragment. Science 240, 1041-1043 (1988).
8. McCafferty, J., Griffiths, A.D., Winter, G. & Chiswell, D.J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552-554 (1990). (Pubitemid 120015109)
9. Skerra, A. & Plückthun, A. Assembly of a functional immunoglobulin Fv fragment in Escherichia coli. Science 240, 1038-1041 (1988).
10. Batra, S.K., Jain, M., Wittel, U.A., Chauhan, S.C. & Colcher, D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol. 13, 603-608 (2002). (Pubitemid 35448063)
11. Jain, R.K. Barriers to drug delivery in solid tumors. Sci. Am. 271, 58-65 (1994).
12. Jain, R.K. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50, 814s-819s (1990).
13. Yokota, T., Milenic, D.E., Whitlow, M. & Schlom, J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 52, 3402-3408 (1992).
14. Schmidt, M.M. & Wittrup, K.D. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol. Cancer Ther. 8, 2861-2871 (2009).
15. Kim, K.M. et al. Anti-CD30 diabody-drug conjugates with potent antitumor activity. Mol. Cancer Ther. 7, 2486-2497 (2008).
16. Zhang, Y. & Pastan, I. High shed antigen levels within tumors: an additional barrier to immunoconjugate therapy. Clin. Cancer Res. 14, 7981-7986 (2008).
17. Ricart, A.D. & Tolcher, A.W. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat. Clin. Pract. Oncol. 4, 245-255 (2007). (Pubitemid 46510534)
18. Baselga, J. et al. Phase ii study of efficacy, Safety, And pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J. Clin. Oncol. 23, 2162-2171 (2005). (Pubitemid 46218708)
19. Krop, I.E. et al. Phase i study of trastuzumab-DM1, An HER2 antibody-drug conjugate, Given every 3 weeks to patients with HER2-positive metastatic breast cancer. J. Clin. Oncol. 28, 2698-2704 (2010).
20. Hudis, C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007). (Pubitemid 47026733)
21. Saleh, M.N. et al. Phase i trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with lewis Y-expressing epithelial tumors. J. Clin. Oncol. 18, 2282-2292 (2000). (Pubitemid 30350221)
22. Connors, J.M. Radioimmunotherapy-hot new treatment for lymphoma. N. Engl. J. Med. 352, 496-498 (2005).
23. Scott, A.M. Radioimmunotherapy of prostate cancer: does tumor size matter? J. Clin. Oncol. 23, 4567-4569 (2005). (Pubitemid 46224054)
24. Milowsky, M.I. et al. Vascular targeted therapy with anti-prostate- specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol. 25, 540-547 (2007). (Pubitemid 350002961)
25. Bander, N.H., Milowsky, M.I., Nanus, D.M., Kostakoglu, L., Vallabhajosula, S. & Goldsmith, S.J. Phase i trial of 177lutetium-labeled J591, A monoclonal antibody to prostate-specific membrane antigen, In patients with androgenindependent prostate cancer. J. Clin. Oncol. 23, 4591-4601 (2005). (Pubitemid 46224061)
26. Milowsky, M.I., Nanus, D.M., Kostakoglu, L., Vallabhajosula, S., Goldsmith, S.J. & Bander, N.H. Phase i trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22, 2522-2531 (2004). (Pubitemid 41103739)
27. Reardon, D.A. et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase ii study results. J. Clin. Oncol. 24, 115-122 (2006). (Pubitemid 46630502)
28. Bleumer, I. et al. A phase ii trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 90, 985-990 (2004). (Pubitemid 38495816)
29. Wu, A.M. & Senter, P.D. Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. 23, 1137-1146 (2005). (Pubitemid 41486395)
30. Tolcher, A.W. et al. A phase i study of huC242-DM4 to assess the safety and pharmacokinetics of huC242-DM4 administered as a single intravenous infusion once every three weeks to subjects with solid tumors. Eur. J. Cancer (suppl. 4) (2006) Abstr 212.
31. Qin, A. et al. The pharmacokinetics and pharmacodynamics of iMGN242 (huC242-DM4) in patients with Canag-expressing solid tumors. J. Clin. Oncol. 26 (2008) Abstr 3066.
32. Lewis Phillips, G.D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, An antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280-9290 (2008).
33. Vogel, C.L. et al. A phase ii study of trastuzumab-DM1 (T-DM1), A HER2 antibody-drug conjugate (aDC), In patients (pts) with HER2+ metastatic breast cancer (MBC): final results. J. Clin. Oncol. 27 (2009) Abstr 1017.
34. Krop, I. et al. A phase 2 study of trastuzumab-DM1 (T-DM1), A novel HER2 antibody-drug conjugate, In HER2+ metastatic breast cancer (MBC) patients previously treated with conventional chemotherapy, Lapatinib and trastuzumab. 32nd annual San antonio Breast Cancer Symposium (2009) Abstr 710.
35. Perez, E.A. et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cáncer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, Multicenter, Open-label phase 2 study (TDM4450G). Ann. Oncol. 21, Vii2 (2010) Abstr LBa3.
36. Woll, P.J. et al. Clinical experience of iMGN901 (BB-10901, HuN901-DM1) in patients with Merkel Cell Carcinoma (MCC). AaCR-NCi-EORTC international Conference; Molecular Targets and Cancer Therapeutics (2009) Abstr 237.
37. Galsky, M.D. et al. Phase i trial of the prostate-specific membrane antigendirected immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 26, 2147-2154 (2008).
38. Hwu, P. et al. A phase i/ii study of CR011-vcMMaE, An antibody-drug conjugate (aDC) targeting glycoprotein NMB (GpNMB) in patients (pts) with advanced melanoma. J. Clin. Oncol. 27, (2009) Abstr 9032.
39. Jackson, D. et al. A human antibody-drug conjugate targeting Epha2 inhibits tumor growth in vivo. Cancer Res. 68, 9367-9374 (2008).
40. Oflazoglu, E. et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin. Cancer Res. 14, 6171-6180 (2008).
41. Kreitman, R.J. et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345, 241-247 (2001). (Pubitemid 32695063)
42. Kreitman, R.J. et al. Phase ii trial of recombinant immunotoxin RFB4(dsFv)-pE38 (BL22) in patients with hairy cell leukemia. J. Clin. Oncol. 27, 2983-2990 (2009).
43. Kreitman, R.J. et al. Phase i trial of recombinant immunotoxin RFB4(dsFv)-pE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol. 23, 6719-6729 (2005). (Pubitemid 46190267)
44. Hassan, R. et al. Phase i study of SS1p, A recombinant anti-mesothelin immunotoxin given as a bolus i.V. Infusion to patients with mesothelinexpressing mesothelioma, Ovarian, And pancreatic cancers. Clin. Cancer Res. 13, 5144-5149 (2007). (Pubitemid 47502082)
45. Akizawa, H. & Arano, Y. Altering pharmacokinetics of radiolabeled antibodies by the interposition of metabolizable linkages. Metabolizable linkers and pharmacokinetics of monoclonal antibodies. Q. J. Nucl. Med. 46, 206-223 (2002). (Pubitemid 35203314)
46. DeNardo, G.L. et al. Preclinical evaluation of cathepsin-degradable peptide linkers for radioimmunoconjugates. Clin. Cancer Res. 9, 3865S-3872S (2003).
47. Kukis, D.L., Novak-Hofer, I. & DeNardo, S.J. Cleavable linkers to enhance selectivity of antibody-targeted therapy of cancer. Cancer Biother. Radiopharm. 16, 457-467 (2001). (Pubitemid 34024434)
48. Nelson, A.L. & Reichert, J.M. Development trends for therapeutic antibody fragments. Nat. Biotechnol. 27, 331-337 (2009).
49. Bruno, R., Washington, C.B., Lu, J.F., Lieberman, G., Banken, L. & Klein, P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother. Pharmacol. 56, 361-369 (2005). (Pubitemid 41095399)
50. Rowinsky, E.K. Curtailing the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies. Clin. Cancer Res. 10, 4220s-4226s (2004). (Pubitemid 38812450)